Chimerix, Inc.
2505 Meridian Parkway
Ste 340
Durham
North Carolina
27713
United States
Tel: 919-806-1074
Fax: 919-806-1146
Website: http://www.chimerix-inc.com/
306 articles with Chimerix, Inc.
-
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
3/2/2023
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided an operational update.
-
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
2/28/2023
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET.
-
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
2/23/2023
Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2022, and to provide a business overview.
-
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
Chimerix announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.
-
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
12/8/2022
Chimerix (NASDAQ:CMRX) today provided an operational update and announced the successful launch of the ONC201 Phase 3 ACTION study at the recent Society for Neuro Oncology (SNO) Conference, which took place November 16-20, 2022 in Tampa, Florida.
-
Chimerix Responds to Rubric Capital Management
11/10/2022
Chimerix issued the following statement regarding a press release issued by Rubric Capital Management:
-
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
11/3/2022
Chimerix reported financial results for the third quarter ended September 30, 2022 and provided an operational update.
-
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
10/27/2022
Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, November 3, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022, and to provide a business overview.
-
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
9/26/2022
Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the closing of its sale of TEMBEXA® to Emergent BioSolutions Inc. (EBS or Emergent).
-
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
8/29/2022
Chimerix today announced that is has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of TEMBEXA® to the U.S. government.
-
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
-
Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
8/8/2022
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an operational update.
-
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive
8/8/2022
Chimerix today appointed Christopher L. Jordan as Vice President, Regulatory Affairs.
-
Chimerix to Present at Wedbush PacGrow Healthcare Conference
8/2/2022
Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m.
-
Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
8/1/2022
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business overview.
-
WHO declared the monkeypox outbreak a “public health emergency of international concern [PHEIC].” As COVID-19 wanes, Tonix, SIGA, Emergent Bio and others are now targeting monkeypox.
-
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
6/24/2022
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA®.
-
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
6/23/2022
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a $9.3 million agreement to procure TEMBEXA ® (brincidofovir) with a third party outside of North America, with authorization from the requisite healthcare authority.
-
Chimerix to Present at Jefferies Global Healthcare Conference - June 01, 2022
6/1/2022
Chimerix announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.
-
Chimerix to Present at H.C. Wainwright Global Investment Conference
5/17/2022
Chimerix announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright Global Investment Conference made available on Tuesday, May 24, 2022 at 7:00 a.m. ET.